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Abstract: The almiramide N-methylated lipopeptides exhibit promising activity against trypanoso-
matid parasites. A structure–activity relationship study has been performed to examine the influ-
ences of N-methylation and conformation on activity against various strains of leishmaniasis proto-
zoan and on cytotoxicity. The synthesis and biological analysis of twenty-five analogs demonstrated 
that derivatives with a single methyl group on either the first or fifth residue amide nitrogen exhib-
ited greater activity than the permethylated peptides and relatively high potency against resistant 
strains. Replacement of amino amide residues in the peptide, by turn inducing α-amino γ-lactam 
(Agl) and N-aminoimidazalone (Nai) counterparts, reduced typically anti-parasitic activity; how-
ever, peptide amides possessing Agl residues at the second residue retained significant potency in 
the unmethylated and permethylated series. Systematic study of the effects of methylation and turn 
geometry on anti-parasitic activity indicated the relevance of an extended conformer about the cen-
tral residues, and conformational mobility by tertiary amide isomerization and turn geometry at the 
extremities of the active peptides. 
Keywords: almiramide; leishmaniasis, N-methylated peptide (List three to ten pertinent keywords 
specific to the article; yet reasonably common within the subject discipline.) 
 
1. Introduction 
Neglected tropical diseases caused by trypanosomatid protozoan infections, such as 
human African trypanosomiasis, Chagas disease and leishmaniasis, impact significantly 
on public health, especially in tropical countries, where their influences are compounded 
due to poverty, environment, and drug resistance [1–3]. Leishmaniasis is caused by an 
intracellular protozoan belonging to the genus Leishmania (L.) and transmitted by the 
phlebotomine sandflies [4]. Upon mammal host infection by way of a sand fly bite, the 
parasites enter the blood cells in the so-called promastigote stage, then begin to multiply 
in the amastigote stage spreading to other cells and tissues. Depending on the species, the 
parasites may disperse via blood and lymph fluid to other body sites, such as the skin and 
major organs. 
With over 1 million new cases occurring annually, around 12 to 15 million people 
worldwide are infected with leishmaniasis [5,6], which presents as four main forms: cu-
taneous, mucocutaneous, visceral and post Kala-azar dermal leishmaniasis (CL, MCL, VL 
and PKDL) [7]. Leishmaniasis causes enlargement of the spleen and liver, anemia [8], skin 
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lesions [9], and destruction of mucous membranes [10]. In addition, controlling co-infec-
tion with HIV and visceral leishmaniasis has become a serious challenge [11]. 
In the absence of a vaccine, chemotherapy is the main tool to treat leishmaniasis, but 
only a few drugs are used clinically [12]. Pentavalent antimonial drugs, such as sodium 
stibogluconate and meglumine antimoniate, were first-line defenses against leishmania 
since the 1940s [13], but are now failing as treatments due to resistance [14]. Amphotericin 
B, which was discovered in the late 1950s, became an alternative drug for treating leish-
maniasis patients [15]. Miltefosine was the first oral anti-leishmanial agent and has been 
used to treat VL patients since 2002 [16]. High cost and side effects have; however, limited 
the use of amphotericin B and miltefosine [17]. The aminoglycoside antibiotic paromomy-
cin has been used to treat leishmaniasis [18], with variations in efficacy contingent upon 
geographic region [19]. 
The need for new anti-leishmanial agents is critical due to limitations in availability 
of effective drugs and the rise of drug resistant strains of leishmaniasis [20]. In the search 
for antiparasitic agents, selectivity and potency (μM) against certain Leishmania strains 
have been observed using chromone natural products [21] and artemisinin-inspired ana-
logs [22]. Moreover, notable differences in ribosomal structure were exploited to conceive 
paromomycin derivatives with potent anti-leishmanial activity and low ototoxicity [23]. 
Other anti-leishmanial agents under investigation include mitochondrial cytochrome bc1 
and pteridine reductase 1 inhibitors, as well as aryl nicotinic acid derivatives [20]. In ad-
dition, the kinetoplastid-selective proteasome inhibitor LXE408 which exhibited efficacy 
in murine CL and VL models has recently entered Phase 1 human clinical trials [24]. 
Almiramides A-C (1–3, Figure 1) are N-methylated linear lipopeptides isolated from 
the marine cyanobacterium Lyngbya majuscula [25]. Certain almiramide analogs have ex-
hibited low µM anti-parasitic activity against the causative pathogen of fatal leishmania-
sis, as well as a high therapeutic index [25]. Almiramide derivatives are attractive leads 
for developing agents against leishmaniasis, in part due to their likely mechanism of ac-
tion involving disruption of the vital energy machinery proteins of the glycosome [26]. A 
peroxisome-related organelle without mammalian counterpart, the glycosome performs 
vital metabolic processes in trypanosomatids [27,28]. In search of glycosome targeting 
agents, the interface of two key transport proteins [peroxin (PEX)14−PEX5] has been 
blocked by pyrazolo[4,3-c]pyridines which killed effectively the causative trypanosoma-
tids of Human African trypanosomiasis and Chagas disease, Trypanosoma brucei and Tryp-
anosoma cruzi, and had low mammalian cell cytotoxicity [29,30]. Moreover, an examination 
of almiramide analogs in affinity capture, and fluorescent microscopy experiments on T. 
brucei, identified the glycosome proteins PEX11 and glycosomal integral membrane pro-
tein-5a (GIM5A) as likely targets [26]. 
Preliminary structure–activity relationship studies on the almiramides have indi-
cated the importance of the unsaturated lipophilic terminus. Almiramides B and C (2 and 
3, Figure 1) with 2-methyl-7-octynoyl and -7-octenoyl tails were reported to exhibit low 
μM activity against Leishmania donovani, but their 2-methyl-7-oxooctanoyl counterpart al-
miramide A (1) was inactive [25]. Employment of a 6-heptynyl lipophilic terminus and N-
methy1 valine3 in acid 12 and dimethyl amide 13 gave peptides with μM IC50 values 
against L. donovani, and improved therapeutic indices with relatively lower cytotoxicity 
(CC50) against mammalian Vero kidney cells: selectivity index (CC50/EC50) 12 = 13 (50.2) > 
2 (21.8) > 3 (17.4) [25]. In this series, the significance of the peptide C-terminal was illus-
trated by the methyl ester counterpart (e.g., 14) of peptide acid 12, which exhibited a sig-
nificant loss of anti-parasitic activity and a relative gain in Vero cell cytotoxicity [25]. In 
addition, peptide 2 and novel almiramides D-H (4–8) possessing the common 2-methyl-
7-octynoyl N-terminus and a distinct N-(Me)Ile4 residue were isolated together from ma-
rine benthic cyanobacteria in a study that found 2 and 9 exhibited toxicity against human 
gingival fibroblast cells [31]. 




Figure 1. Natural almiramides A-H (1–8) and carbohydrate and C-terminal derivatives 9–14. 
The active almiramide conformation has been examined by replacement of the Val3-
Ala4 dipeptide moiety with a mannose-derived furanose amino acid in analogs 9–11. 
Sugar-peptide hybrids 9–11 exhibited a similar activity and selectivity index as miltefosine 
against intra-macrophage amastigotes of L. donovani and Vero cells [32]. Conformational 
analysis of sugar-peptide hybrids 9 and 11, by a combination of computational and NMR 
spectroscopic methods, concluded a potential bent structure from a characteristic nuclear 
Overhauser effect correlation between the phenylalanine N-methyl group and the d-pro-
ton of the furanose amino acid residue [32]. 
The intriguing potential of the almiramides for the development of anti-parasitic 
agents has prompted a more detailed study to ascertain the features responsible for their 
potency and selectivity. In spite earlier efforts, limited knowledge exists of the relevance 
of N-methylation and conformation for almiramide activity against parasite and host cells. 
Among the reported almiramide analogs, peptides having only two N-methyl residues 





















Almiramide R1 R2 R3 R4 R5 R6
 A (1) -CH2-CO-CH3 Me H Me Me Bn
B (2) C CH-CH2 Me H Me Me Bn
C (3) CH=CH2-CH2 Me H Me Me Bn
D (4)
C CH-CH2
Me Me sec-butyl H Me
E (5)
C CH-CH2
H Me sec-butyl H Me
F (6) C CH-CH2
Me Me sec-butyl H CH2OH
G (7) C CH-CH2 Me H sec-butyl H Me
H (8) C CH-CH2

































X = 12, OH; 13, N(CH3)2; 14, OCH3
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been respectively isolated and synthesized. To the best of our knowledge, the activity of 
unmethylated and singly methylated almiramide peptides has yet to be reported nor has 
the effectiveness of almiramide analogs against resistant strains of Leishmania been exam-
ined. A systematic study of almiramide peptides has now been performed to shine light 
on the importance of tertiary amides and turn conformers for activity against Leishmania 
and resistant strains. 
2. Results and Discussion 
2.1. Chemistry 
Commencing with the potent and selective lead peptide 12, a systematic study of the 
influence of N-methyl groups on each of the five amides was begun by the preparation of 
the corresponding unmethylated peptide acid 15 (Figure 2). Considering that long chain 
secondary amide derivatives of 12 retained significant anti-parasitic activity and offered 
potential for the synthesis of conjugates to study mechanism of action [26], the corre-
sponding 1,6-hexanediamine amides 16 and 17 were examined for comparison with per-
methylated and unmethylated acids 12 and 15. Subsequently, an N-methyl scan was per-
formed on amide 16 to provide singly methylated analogs 18–22. For systematic solid-
phase syntheses of N-methyl peptides 18–22, the required N-methyl amino acids (Fmoc-
Ala(Me)-OH, Fmoc-Phe(Me)-OH and Fmoc-Val(Me)-OH) were respectively prepared in 
solution, according to literature protocols featuring acid-catalyzed condensation of an 
Fmoc-protected amino acid with paraformaldehyde, to form an oxazolidinone followed 
by reduction with triethyl silane and trifluoroacetic acid [33]. 
In the study of biologically active peptides, α-amino γ-lactam residues (Agl residues, 
Figure 2) so-called Freidinger-Veber lactams have been commonly used to restrict back-
bone ω and ψ dihedral angles to favor β-turn conformers, in which the Agl residue situates 
at the i + 1 position [34,35]. The related N-amino-imidazol-2-one (Nai) residues offer sim-
ilar backbone constraint with potential to add substituents at the heterocycle 4- and 5-
positions to mimic side chain function with constrained χ dihedral angle geometry [35,36]. 
A biologically active almiramide bent conformer has been proposed based on the activity 
of sugar-peptide hybrids 9–11 [32]. To probe this hypothesis further, Agl and (5-Me)Nai 
residues were used to replace systematically the first four residues in the sequences of 
peptides 12 and 15–17 (Figure 3). For example, six Agl almiramide derivatives (e.g., 23–
28) were respectively prepared by replacing valine (e.g., Val1, Val2, Val3) with the hetero-
cycle in acids 12 and 15. The first four residues of permethylated and unmethylated pep-
tide amides 16 and 17 were also systematically replaced by Agl residues to provide pep-
tides 29–35. Moreover, (5-Me)Nai residues were respectively used to replace Val1 and Val2 
of peptide acid 15 in peptides 36 and 37. 
For the Agl scan, Fmoc-Agl dipeptides [Fmoc-Agl-Val-OH, Fmoc-Agl-Ala-OH and 
Fmoc-Agl-Phe-OH (38a–c), supporting information] were respectively synthesized by a 
modification of the original Freidinger-Veber protocol, as recently reported for the prep-
aration of the valine dipeptide [34,37]. In brief, N-(Boc)methionyl dipeptide tert-butyl es-
ters were treated with iodomethane to prepare the corresponding sulfonium ion interme-
diate, which on treatment with NaH underwent intramolecular N-alkylation to furnish N-
(Boc)Agl dipeptide tert-butyl esters (e.g., 39a–c, supporting information). The carbamate 
and ester groups were removed using trifluoroacetic acid (TFA) in dichloromethane and 
the Fmoc group was installed using N-(9-fluorenylmethoxycarbonyloxy)succinimide 
(Fmoc-OSu) and sodium carbonate in aqueous acetone to provide Agl dipeptides 38. Dur-
ing the cyclization to form Boc-Agl-Phe-Ot-Bu (39c, supporting information), ester epi-
merization occurred providing an inseparable 2:1 mixture of diastereomers, which was 
used to prepare the separable mixture of Agl-Phe peptide 32 and Agl-D-Phe isomer R-32. 
The corresponding Nai-dipeptide ester [Fmoc-(5-Me)Nai-Val-Ot-Bu (40, supporting infor-
mation)] was synthesized from Fmoc-azaGly-Val-Ot-Bu (41, supporting information), by 
a route featuring oxidation to the corresponding azopeptide using N-bromosuccinimide 
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(NBS) and lutidine in dichloromethane, proline-catalyzed alkylation with propionalde-
hyde, and dehydration using p-toluenesulfonic acid in chloroform [38]. Ester solvolysis 
using TFA in dichloromethane gave the Fmoc-(5-Me)Nai-Val-OH which without purifi-
cation was coupled onto resin. 
 
Figure 2. N-Methyl scan of almiramide analogs. 
 


















Peptide R1 R2 R3 R4 R5 X
15 H H H H H OH
16 H H H H H NH(CH2)6NH2
17 Me Me Me Me Me NH(CH2)6NH2
18 Me H H H H NH(CH2)6NH2
19 H Me H H H NH(CH2)6NH2
20 H H Me H H NH(CH2)6NH2
21 H H H Me H NH(CH2)6NH2
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As illustrated by the synthesis of Agl analog 24, peptides 15–37, all were synthesized 
using conventional Fmoc/t-Bu solid phase peptide synthesis (SPPS) methods starting from 
chlorotrityl resin (CTC resin, Scheme 1) [25,39]. N-Methyl peptide amides 18–22 were syn-
thesized on CTC resin modified with a 1,6-diaminohexane linker. 1,6-Diaminohexane was 
loaded onto the CTC resin using N,N′-diisopropylethylamine. 
 
Scheme 1. Representative SPPS (solid phase peptide synthesis) synthesis of almiramides deriva-
tives 24 and 30. 
N-(9-Fluorenylmethoxycarbonyl)phenylalanine was coupled to CTC resin using 
N,N’-diisopropylethylamine. Alternatively, Fmoc-Phe-OH and Fmoc-Phe(Me)-OH were 
coupled to 1,6-diaminohexane CTC resin using N,N’-diisopropylcarbodiimide (DIC) and 
1-hydroxybenzotriazole (HOBt) in NMP. After Fmoc group removals with a 20% solution 
of piperidine in DMF, Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc-Agl dipeptide acids 38a-c, 
Fmoc-(5-Me)Nai-Val-OH and 6-heptynoic acid, all were respectively coupled using a sim-
ilar DIC/HOBt protocol. The N-methyl residues (e.g., Fmoc-Ala(Me)-OH and Fmoc-
Val(Me)-OH) were coupled using 1-[bis(dimethylamino)methylene]-1H-1,2,3-tria-
zolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) and N-methylmorpholine in 
DMF [40]. Peptide cleavage was performed using a TFA/TES/H2O (95:2.5:2.5) cocktail. Fi-
nal peptides were precipitated with diethyl ether (Et2O) and purified by HPLC on a C18 
column (Table 1). Peptide acids (e.g., 24) were permethylated using sodium hydride and 
iodomethane in THF (Scheme 2) [25]. As illustrated for the synthesis of amide 34, un-
methylated and permethylated peptide amides 16 and 17, as well as Agl peptide amides 
29-35, all were prepared by coupling the corresponding peptide acids (e.g., 27) to 1,6-dia-










= a, O-CTC resin; 
   b, HN(CH2)6NH-CTC resin
1) 20% piperidine, DMF
2) Fmoc-Val-OH, DIC, HOBt, NMP
3) 20% piperidine, DMF












Scheme 2. Representative permethylation of peptide acid 24 and coupling to 1,6-diaminohexane to prepare peptide amide 
34. 
Table 1. Purity, retention times, and mass of almiramide derivatives. 
# 
Sequences 
(R- = HCC(CH2)4CO-) 
RT Purity at 
214 nm 
MS [M + 1] 




6.83 a 7.19 >99 734.4463 734.4468 
15 R-Val-Val-Val-Ala-Phe-OH 8.83 a 7.44 >99 642.3861 642.3865 
























7.62 a 6.62 >99 754.5225 754.5225 
23 R-Agl-Val-Val-Ala-Phe-OH 7.11 c 6.71 >99 626.3548 626.3523 
24 R-Val-Agl-Val-Ala-Phe-OH 7.55 c 6.87 >99 626.3548 626.3529 












9.01 c 8.43 >99 704.3993d 704.3964d 
29 R-Agl-Val-Val-Ala-Phe-NH(CH2)6NH2 6.72 a 6.00 >94 724.4756 724.4763 
30 R-Val-Agl-Val-Ala-Phe-NH(CH2)6NH2 6.83 a 5.98 >96 724.4756 724.4774 
31 R-Val-Val-Agl-Ala-Phe-NH(CH2)6NH2 7.50 c 6.44 >99 724.4756 724.4768 
32 R-Val-Val-Val-Agl-Phe-NH(CH2)6NH2 5.31 b 6.42 >92 752.5069 752.5082 
R-32 R-Val-Val-Val-Agl-D-Phe-NH(CH2)6NH2 5.07 b 6.42 >94 752.5069 752.5072 














6.80 c 7.18 >99 780.5382 780.5394 
36 R-(5-Me)Nai-Val-Val-Ala-Phe-OH 5.34 c 6.48 >99 639.3501 639.3474 
37 R-Val-(5-Me)Nai-Val-Ala-Phe-OH 4.41 c 8.68 >96 639.3501 - 
Isolated purity ascertained by LC-MS analysis using gradients of X−Y% A [H2O (0.1% FA)/MeOH (0.1% FA)] or B [H2O 
(0.1% FA)/MeCN (0.1% FA)] over Z min: a 30−95% A/14. b 10−90% B/14; c 50−90% A/14. d [M + Na]. 
2.2. Bioactivity 
The biological activity of peptides 15–37 was assessed against the L. infantum wild-
type stain (WT), as well as mutants resistant to the common anti-leishmanial agents, such 
as antimony (SbIII), amphotericin B (AmB) and miltefosine (MF): Sb2000.1, AmB1000.1 and 
MF200.5. Activity against Leishmania promastigotes was determined by monitoring the 
replication of parasites after 72 h of incubation at 25 °C in the presence of increasing con-
centrations of the different peptides 12–37 and reported as EC50 values (Table 2). In gen-
eral, almiramide peptides 12–37 exhibited activity against wild type and resistant strains 
in the range of 5–300 μM. The greatest potencies were observed using analogs against the 
amphotericin B resistant strain (e.g., AmB1000.1). 




(R- = HCC(CH2)4CO-) 
Ldi WT 1 
(μM) 
Ldi Sb-Res 2 
(μM) 
Ldi MF-Res 3 
(μM) 





































































































































25 R-Val-Val-Agl-Ala-Phe-OH N.D. N.D. N.D. N.D. 416 - 










































































































































N.D. N.D. N.D. N.D. 407 - 
1 = Leishmania infantum (MHOM/MA/67/ITMAP-263) wild-type strain. 2 = Leishmania infantum (MHOM/MA/67/ITMAP-
263) resistant to 2 mM trivalent (and pentavalent) antimonials. 3 = Leishmania infantum (MHOM/MA/67/ITMAP-263) re-
sistant to 200 µM miltefosine. 4 = Leishmania infantum (MHOM/MA/67/ITMAP-263) resistant to 1 µM amphotericin B. 95% 
confidence intervals for EC50 determinations are reported within brackets (n = 3). SI = selectivity index = CC50/EC50 Ldi WT. 
N.D. = Non disponible = >300 μM. 
Examining peptide potency (EC50) against wild type L. infantum, the 1,6-diaminohex-
ane amides (e.g., 16 and 17) were respectively more potent than the acid counterparts (e.g., 
15 and 12). In the Agl series, amides 29–31 and 33–35 were similarly more active than their 
acid counterparts 23–25 and 26–28. Moreover, the unmethylated analogs (e.g., 15, 16, 29 
and 31) were typically more potent than the respective permethylated counterparts (e.g., 
12, 17, 33 and 35), except in the case of Agl2 analogs 30 and 34. Comparison of the activity 
of unmethylated 1,6-diaminohexane amide 16 with singly methylated counterparts 18–22 
illustrated decreasing potency in the order of 16 > MePhe5 22 > MeVal1 18 > MeVal3 20 > 
MeAla4 21 > MeVal2 19. Considering the Agl analogs as constrained versions of the corre-
sponding N-methyl dipeptide amides, except in the case of MePhe 22 which was signifi-
cantly more potent than Agl-Phe 32, the more restricted Agl analogs 29–31 were slightly 
more active than their N-methyl counterparts 19–21. Activity against Leishmania dropped 
significantly in the case of the Agl peptide acids (23–28) and their (5-Me)Nai counterparts 
(36 and 37). 
Many of the structure–activity relationships, that were observed in the wild-type 
strain, were also found in the resistant strains. For example, the amides were more potent 
than their acid counterparts. The nonmethylated analogs were also typically more potent 
than their permethylated analogs; however, in the case of the amphotericin B resistant 
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strain (e.g., AmB1000.1), permethylated analogs 17 and 35 were respectively 4- and 1.4-
fold more active than nonmethylated counterparts 16 and 31, and in the case of the 
miltefosine resistant strain (e.g., MF200.5), 35 was 1.5-fold more active than 31. Although 
the order of potency for nonmethylated 16, MeVal1 18 and MePhe5 22 was contingent on 
the tested resistant strain, analogs with no tertiary amide and methylation at the C- and 
N-terminal residues were consistently more active than peptides 19–21 with N-methyla-
tion in the central residues. The potency of MePhe5 22 was greater than Agl-Phe5 32 for all 
strains tested. The Agl constraint at other positions tended to slightly favor activity com-
pared to the tertiary amide counterpart in the antimony resistant strain (e.g., Sb2000.1) as 
was observed in wild type; however, the lactam analogs were significantly less active than 
the respective N-methyl counterparts against the miltefosine and amphotericin B strains. 
In addition, preliminary investigations of peptides (e.g., 12–22), which had notable po-
tency against Leishmania (EC50 = 5–90 μM), detected no activity against T. brucei and T. 
cruzi (data not shown). 
The host cytotoxicity was evaluated by monitoring the survival rates of murine LM-
1 macrophage at different concentrations of peptides 15–37 (0.0001 to 100 mM) over 24 h. 
Most analogs exhibited CC50 values between 170–450 μM. Exceptionally, MeAla peptide 
amide 21 was 3.2- to 8-fold less toxic than the other peptide analogs. Comparing macro-
phage toxicity with potency against L. infantum, the selectivity index (SI) for MeAla pep-
tide amide 21 was relatively high (SI = 19.1) and comparable with the most potent peptide 
(e.g., 16, SI = 19.2). In comparisons of macrophage toxicity with potency against the AmB 
resistant Leishmania strain, permethylated and MeVal1 peptide amides 17 and 18 exhibited, 
respectively, therapeutic indices of 64 and 36. 
3. Discussion 
The structure–activity relationship studies obtained in wild type and resistant strains 
of L. infantum reflect likely a combination of ability to engage the target and pharmacoki-
netic properties that may influence peptide availability. The molecular targets of almira-
mide C have been studied using a combination of photo-affinity and fluorescent probes 
in T. brucei, and suggested to include integral membrane proteins found in glycosomes 
(e.g., GIM5 and PEX11), which are specific to kinetoplastid parasites [26]. Responsible for 
the first seven steps of glycolysis, the glycosome is a peroxisome-related organelle essen-
tial for parasite survival in the bloodstream stage [41]. Notably, translocation across the 
glycosomal membrane implicates transporter and pore-forming proteins [42], which may 
differ contingent on species and be modified in resistant strains. 
Resistant strains of Leishmania emerge by different mechanisms which contingent on 
the drug act commonly to reduce the active concentration inside the parasite by either 
decreasing uptake, increasing efflux or inhibiting activity [43]. Leishmania antimonial re-
sistance is associated with thiol metabolism to prevent reduction of the SbV to more active 
SbIII, and to sequester antimony in thiolate complexes amenable for efflux [44]. Miltefosine 
resistance is commonly associated with mutations in the Leishmania miltefosine trans-
porter (LMT), a P-type ATPase responsible for the translocation of phospholipids, as well 
as overexpression of ABC transporters [44]. Amphotericin B resistant L. donovani pro-
mastigotes have been shown to feature substitution of ergosterol for another sterol, which 
alters the fluidity and AmB binding affinity in the cell membrane [45]. 
Although the conformational preferences of the almiramides alone and target bound 
have yet to be described, information gleaned from related peptides and their N-methyl 
and lactam counterparts offers a lens through which to interpret the structure–activity 
relationships. For example, the circular dichroism spectrum of the (Val-Val-Val-Ala)n oli-
gomer in a mixture of hexafluoro-2-propanol and trifluoro ethanol indicated a curve 
shape typical of an extended β-sheet structure [46]. The corresponding Val-Val-Val-Ala 
region in nonmethylated almiramide analogs 15 and 16, as well as MePhe analog 22 may 
likely adopt an extended β-strand conformer. Introduction of N-methyl groups causes 
significant consequences on peptide conformation, due in part to creation of a tertiary 
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amide which loses a potential NH hydrogen-bond donor and may adopt energetically 
similar cis and trans isomers [47]. Computational analysis of the N’-methyl amides of N-
acetyl-N-methyl- and N-acetyl-alanine indicated that repulsive interactions between the 
N-methyl and carbonyl oxygen moieties of the former abolished the low-energy minimum 
β-conformer adopted by the latter [48]. In cyclic peptides, N-methyl residues have also 
induced backbone f and ψ dihedral angles consistent with β- and γ-turn conformers [49], 
as well as altered side chain χ geometry [50]. N-Alkylation of the central amide of the 
hairpin inducing D-Pro-Aib dipeptide has also been shown by variable temperature CD 
spectroscopy to reinforce the central turn conformer and enhance the stability of the 
folded β-sheet peptide [51]. Introduction of N-methyl residues within the peptide chain 
causes likely a shift from an extended sequence to a dynamic series of cis- and trans-amide 
conformers exhibiting a preference for turn geometry, which in peptides 19–21 reduces 
activity. In MeVal1 analog 18 and permethylated analogs 12 and 17, methylation at the N-
terminal enables a cis-amide conformer in which the lipid tail may fold in the direction of 
the peptide. Such a geometry may improve membrane transport by hiding hydrophilic 
NH moieties and may account for the significantly improved activity of 17 and 18 against 
the amphotericin B resistant strains. To further examine the influence of N-methylation 
on conformation, the 1H NMR spectra of nonmethylated peptide 16 and N-methyl coun-
terpart 18 were examined in DMSO-d6 (supporting information). In contrast to peptide 16, 
which exhibited a narrow distribution of amide protons signals between 7.55 and 7.95 
ppm characteristic of a linear conformer, the corresponding peaks were downfield shifted, 
dispersed between 7.65 and 8.35 ppm, and existed in isomeric pairs for MeVal1 peptide 
18, likely due the tertiary amides favoring cis- and trans-amide isomers of similar energy 
and local turn conformers with intramolecular hydrogen bonds. 
The propensity for Agl bearing peptides to adopt type II and II’ β-turns contingent 
on α-carbon stereochemistry has been demonstrated using spectroscopic and computa-
tional methods, as well as X-ray diffraction, which has also characterized crystals of lac-
tam analog in extended conformers [52]. Relatively diminished activities of Agl analogs 
29–35 compared to nonmethylated peptide 16 may again be due to the favored turn ge-
ometry. The slightly better activity exhibited by Agl analogs 29–31 in comparison to N-
methyl counterparts 19–21 in wild type L. infantum may be attributed to the capacity of 
the amino lactam to stabilize trans-amide isomers. On the other hand, the notably better 
activity of MePhe analog 22 relative to Agl counterpart 32 indicates the attributes of 
greater conformational flexibility at the C-terminal. Similarly, greater conformational dy-
namics of N-methyl analogs compared to the Agl counterparts appear to be important for 
the relatively better activity of the former in resistant Leishmania strains. 
4. Materials and Methods 
4.1. Experimental Section 
4.1.1. Leishmania Cultures and Antileishmanial Activity Determination 
The L. infantum (MHOM/MA/67/ITMAP-263) wild-type stain (WT), as well as the re-
sistant mutants Sb2000.1, AmB1000.1 and MF200.5 [53–58], resistant to antimony (SbIII), 
amphotericin B (AmB) and miltefosine (MF), respectively, were grown in M199 medium 
at 25 °C supplemented with 10% fetal bovine serum, 5 μg/mL of haemin at pH 7.0 and 
2000 μM Sb (Potassium antimonyl tartrate, Sigma-Aldrich), 200 μM of MF (Miltefosine, 
Cayman Chem., Michigan, USA) or 1 μM AmB (Amphotericin B solution, Sigma, 
Oakville, Canada). Antileishmanial values were determined in Leishmania promastigotes 
by monitoring the replication of parasites after 72 h of incubation at 25 °C in the presence 
of increasing concentrations of the different peptides by measuring A600 using a Cytation 
5 machine (BioTek, Vermont, USA). EC50 values were calculated based on dose–response 
curves analyzed by non-linear regression with GraphPad Prism 8.4.3 software (GraphPad 
Software, La Jolla, CA, USA). An average of at least three independent biological repli-
cates from independent cultures was performed for each determination. 
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4.1.2. LM-1 Macrophages and Cytotoxicity Determination 
The LM1- macrophages were grown in DMEM supplemented with 10% heat inacti-
vated FBS. Cells at the concentration of 100,000 cells/mL were cultivated for 24 h in a 96-
well plate (37 °C, 5% CO2). The culture medium was removed and fresh medium contain-
ing the appropriate drug and concentration was added to the cells, which were incubated 
for 24 h (37 °C, 5% CO2). Seven different concentrations were tested (100, 10, 1, 0.1, 0.01, 
0.001 and 0.0001 mM) as well as controls (without drugs). After 24 h, the culture medium 
was removed and replaced for fresh medium containing 10% Alamar Blue (Thermo Fisher 
Scientific, Massachusetts, USA) and incubated for 2 h (37 °C, 5% CO2). Readings at 570 
and 600 nm (Asys UVM340 Plate reader, Biochrom, Cambridge, UK) were taken and an-
alyzed according to the manufacturer protocol. Survival rates at different drug concentra-
tions and CC50 values were calculated using the Excel software. 
4.2. Materials 
Anhydrous solvents (THF, DMF, CH2Cl2, and NMP) were obtained by passage 
through solvent filtration systems (GlassContour, Irvine, CA, USA). Unless specified oth-
erwise, all reagents from commercial sources were used as received. 2-Chlorotrityl chlo-
ride (CTC) resin (1.46 mmol/g, 100–200 mesh), N-(9-fluorenylmethoxycarbonyloxy)suc-
cinimide (Fmoc-Osu), N,N′-diisopropylcarbodiimide (DIC), all were purchased from 
ChemImpex; 4-dimethylaminopyridine (DMAP), N,N′-dicyclohexylcarbodiimide (DCC), 
iodomethane, N,N-diisopropylethylamine (DIEA), formic acid (FA), all were purchased 
from Aldrich; amino acids, such as Fmoc-Phe-OH, Fmoc-Ala-OH, Fmoc-Val-OH, and 6-
heptynoic acid were purchased from GL Biochem, ChemImpex and Combi-blocks; sol-
vents were obtained from Fisher. Sodium hydride (60% dispersion in mineral oil) was 
washed with hexane three times to remove oil prior to use. The N-methyl amino acids, 
Fmoc-Phe(Me)-OH, Fmoc-Ala(Me)-OH and FmocVal(Me)-OH, were prepared by accord-
ing to the literature procedure and exhibited 1H NMR spectra data identical to that previ-
ously reported [33]. The Agl dipeptide, Fmoc-Agl-Val-OH was prepared according to the 
literature procedure and exhibited a 1H NMR spectrum identical to that previously re-
ported [37]. 
Chromatography was on 230−400 mesh silica gel. Analytical thin-layer chromatog-
raphy (TLC) was performed on glass-backed silica gel plates (Merck 60 F254). Visualiza-
tion of the developed chromatogram was performed by UV absorbance or staining with 
ninhydrin. 1H and 13C NMR spectra were measured respectively in CDCl3 at 500 MHz and 
126 MHz, and referenced to CDCl3 (7.26 and 77.0 ppm). Coupling constants, J values were 
measured in Hertz (Hz) and chemical shift values in parts per million (ppm). Specific ro-
tations, [α]D were measured at 25 °C at the specified concentrations (c in g/100 mL) using 
a 1 dm cell on a PerkinElmer Polarimeter 589 and expressed using the general formula: 
[αD25] = (100 × α)/(d × c). High resolution mass spectral analyses were obtained by the 
Centre Régional de Spectrométrie de Masse de l’Université de Montréal. Protonated mo-
lecular ions [M + H]+ and sodium adducts [M + Na]+ were used for empirical formula con-
firmation. 
Almiramide peptide analog synthesis was performed using Fmoc-based solid-phase 
synthesis in an automated shaker commencing with 2-chlorotrityl chloride resin. All final 
peptides were purified on a preparative column (C18 Gemini column) using a gradient 
from pure water (0.1% FA) to mixtures with MeOH (0.1% FA) at a flow rate of 10 mL/min. 
Purity of peptides (>95%) was evaluated using analytical LC−MS on a 5 μM 50 mm × 4.6 
mm C18 Phenomenex Gemini column in two different solvent systems: water (0.1% FA) 
with CH3CN (0.1% FA) and water (0.1% FA) with MeOH (0.1% FA) at a flow rate of 0.5 
mL/min using the appropriate linear gradient. 





HCC(CH2)4CO-Val(Me)-Val(Me)-Val(Me)-Ala(Me)-Phe(Me)-OH (12) Under ar-
gon, peptide 15 (200 mg) was dissolved in THF (40 mL), cooled to 0 °C, treated with NaH 
(600 mg, 80 eq.), stirred for 5 min, and treated dropwise with iodomethane (0.6 mL, 9 
mmol, 30 eq.). The cooling bath was removed. The reaction mixture warmed to room tem-
perature. After 2 h, more iodomethane (0.6 mL, 30 eq.) was added to the reaction mixture, 
which was stirred for 20 h. The suspension was quenched with water, concentrated to a 
reduced volume, and acidified to pH = 1 using 10% aqueous HCl. The acidified mixture 
was extracted 3 times with EtOAc. The organic layers were combined, dried over Na2SO4, 
filtered and evaporated to 174 mg of residue, from which part (87 mg) was used to make 
peptide 17 as described below, and the remainder was purified by HPLC on a C18 column 
using a gradient of 30% to 90% MeOH in H2O to obtain peptide 12 (16 mg, 13%), which 
was shown to be >99% pure by LC-MS analysis [30−95% MeOH (0.1% FA) in H2O (0.1% 
FA), 14 min, RT 6.83 min]. 
 
15 
HCC(CH2)4CO-Val-Val-Val-Ala-Phe-OH (15) Fmoc-Phe-OH (848 mg, 1.5 eq.) and 
DIEA (0.8 mL, 3 eq.) were added to a suspension of 2-chlorotrityl chloride resin (1 g, 200–
400 mesh, 1% DBV) swollen in CH2Cl2 (25 mL). The mixture was shaken for 18 h, filtered 
and washed sequentially with CH2Cl2 (3 times for 1 min/wash) and DMF (3 times for 1 
min/wash). The Fmoc group was removed upon treatment twice for 20 min with a 20% 
solution of piperidine in DMF (20 mL/g resin). Subsequently, Fmoc-Ala-OH (3 eq.) was 
coupled to the resin swollen in NMP (25 mL/g resin) using DIC (3 eq.) and HOBt (3 eq.). 
After shaking for 16 h, the coupling mixture was filtered, and the resin was washed as 
described above. Subsequent Fmoc group removal and coupling of Fmoc protected amino 
acid residues were performed using the above protocols. Complete coupling reactions 
were confirmed by LC–MS monitoring. After coupling of the last residue, the 6-heptynoic 
acid (3 eq.), DIC (3 eq.) and HOBt (3 eq.) were added to the resin. The mixture was shaken 
for 18 h, filtered and washed as previously described. Then, the linear peptide was cleaved 
from the solid support using a solution of TFA/TES/H2O (95/2.5/2.5). The volatiles were 
evaporated. The reduced volume was treated with diethyl ether. The precipitate was col-
lected by centrifugation (1200 rpm), washed with ether and recollected by centrifugation 
(3 × 10 min). Removal of diethyl ether afforded a colorless solid [2], which gave 387 mg of 
residue, from which 200 mg was used to make peptide 12 as described below, and 60 mg 
purified by HPLC on C18 column using a gradient of 30% to 90% MeOH in H2O to obtain 
peptide 15 (24 mg, 12%) , which was shown to be >99% pure by LC-MS analysis [30−95% 
MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 8.33 min]. 





HCC(CH2)4CO-Val-Val-Val-Ala-Phe-NH(CH2)6NH2 (16) A suspension of 2-chlo-
rotrityl chloride resin (250 mg, 200–400 mesh, 1% DBV) swollen in CH2Cl2 (25 mL) was 
treated with 1,6-diaminohexane (51 mg, 1.2 eq.) and DIEA (0.2 mL, 3 eq.), shaken for 24 h, 
filtered and washed sequentially with CH2Cl2 (3 times for 1 min/wash) and DMF (3 times 
for 1 min/wash). Subsequently, Fmoc-Phe-OH (3 eq.) was coupled to the resin swollen in 
NMP (25 mL/g resin) using DIC (3 eq.) and HOBt (3 eq.). After shaking for 16 h, the cou-
pling mixture was filtered, and the resin was washed as described above. Subsequent 
Fmoc group removals, couplings of Fmoc protected amino acid residues, and acylation 
with 6-heptynoic acid, all were performed using the protocols described for the synthesis 
of peptide 15. The linear peptide was cleaved from the solid support using a solution of 
TFA/TES/H2O (95/2.5/2.5). Removal of the volatiles gave a colorless oil, which was puri-
fied by HPLC on a C18 column using a gradient of 30% to 90% MeOH in H2O to obtain 
peptide 16 as a white solid (8.8 mg, 3%), which was shown to be >99% pure by LC-MS 
analysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.33 min]. 
 
17 
HCC(CH2)4CO-Val(Me)-Val(Me)-Val(Me)-Ala(Me)-Phe(Me)-NH(CH2)6NH2 (17) A 
solution of permethylated peptide 12 (87 mg) in dry CH2Cl2 (15 mL) was treated with 1,6-
hexamethylenediamine (17 mg, 1.2 eq.), DMAP (4 mg, 0.3 eq.), and DCC (30 mg, 1.2 eq.), 
and stirred for 48 h at room temperature. The reaction mixture was filtered through 
Celite™ and washed with CH2Cl2. The filtrate and washings were evaporated under re-
duced pressure. The residue was purified by HPLC on a C18 column using a gradient of 
30% to 90% MeOH in H2O. Evaporation of the collected fractions afforded amino hexan-
amide 17 as white solid (17 mg, 14%), which was shown to be >99% pure by LC-MS anal-
ysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 9.01 min]. 
 
18 
HCC(CH2)4CO-Val(Me)-Val-Val-Ala-Phe-NH(CH2)6NH2 (18) As described for the 
synthesis of peptide 16, 1,6-diaminohexane (51 mg, 1.2 eq.) and DIEA (0.2 mL, 3 eq.) were 
reacted with 2-chlorotrityl chloride resin (250 mg, 200–400 mesh, 1% DBV) in CH2Cl2 (25 
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mL). The resulting amine resin was swollen in NMP (25 mL/g resin), treated with Fmoc-
Phe-OH (3 eq.), DIC (3 eq.) and HOBt (3 eq.), shaken for 16 h, filtered, and washed as 
described above. The Fmoc group was removed upon treatment twice for 20 min with a 
20% solution of piperidine in DMF (20 mL/g resin). After Fmoc group removal, the pep-
tide was elongated, coupled to 6-heptynoic acid using HATU (3 eq.) in 0.4 NMM in DMF 
(25 mL/g resin), cleaved and purified as described for the synthesis of peptide 16. Evapo-
ration of the collected fractions gave peptide 18 (8.2 mg, 3%), which was prepared and 
shown to be >99% pure by LC-MS analysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 
14 min, RT 8.42 min]. 
 
19 
HCC(CH2)4CO-Val-Val(Me)-Val-Ala-Phe-NH(CH2)6NH2 (19) Employing the proto-
col described above for the synthesis of peptide 18 using Fmoc-Val(Me)-OH (386 mg, 3 
eq.) in the fourth coupling, peptide 21 (6.4 mg, 2%) was prepared and shown to be >99% 




HCC(CH2)4CO-Val-Val-Val(Me)-Ala-Phe-NH(CH2)6NH2 (20) Employing the proto-
col described above for the synthesis of peptide 18 using Fmoc-Val(Me)-OH (386 mg, 3 
eq.) in the third coupling, peptide 20 (5.8 mg, 2%) was prepared and shown to be >99% 




HCC(CH2)4CO-Val-Val-Val-Ala(Me)-Phe-NH(CH2)6NH2 (21) Employing the proto-
col described above for the synthesis of peptide 18 using Fmoc-Ala(Me)-OH (355 mg, 3 
eq.), peptide 21 (7.8 mg, 3%) was prepared and shown to be >99% pure by LC-MS analysis 
[30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.61 min] 





HCC(CH2)4CO-Val-Val-Val-Ala-Phe(Me)-NH(CH2)6NH2 (22) Employing the proto-
col described above for the synthesis of peptide 22 using Fmoc-Phe(Me)-OH (528 mg, 3 
eq.), peptide 22 (4.5 mg, 2%) was prepared and shown to be >99% pure by LC-MS analysis 
[30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.62 min]. 
 
23 
HCC(CH2)4CO-Agl-Val-Val-Ala-Phe-OH (23) Employing the protocol described 
above for the synthesis of peptide 15 using Fmoc-Agl-Val-OH (462 mg, 3 eq.) in the third 
coupling, peptide 23 (7.5 mg, 3%) was prepared and shown to be >99% pure by LC-MS 
analysis [50−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.11 min]. 
 
24 
HCC(CH2)4CO-Val-Agl-Val-Ala-Phe-OH (24) Employing the protocol described 
above for the synthesis of peptide 15 using Fmoc-Agl-Val-OH (462 mg, 3 eq.) in the second 
coupling, peptide 24 (8.4 mg, 3%) was prepared and shown to be >99% pure LC-MS anal-
ysis [50−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.55 min]. 
 
25 
HCC(CH2)4CO-Val-Val-Agl-Ala-Phe-OH (25) Employing the protocol described 
above for the synthesis of peptide 15 using Fmoc-Agl-Ala-OH (359 mg, 3 eq.) in the first 
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coupling, peptide 25 (9.1 mg, 3%) was prepared and shown to be >99% pure by LC-MS 
analysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.94 min]. 
 
26 
HCC(CH2)4CO-Agl(Me)-Val-Val(Me)-Ala-Phe(Me)-OH (26) Employing the proto-
col described above for the synthesis of peptide 12 using Fmoc-Agl-Val-OH (462 mg, 3 
eq.) in the third coupling, followed by permethylation, peptide 26 (9.5 mg, 3%) was pre-
pared and shown to be >95% pure by LC-MS analysis [50−90% MeOH (0.1% FA) in H2O 
(0.1% FA), 14 min, RT 8.69 min]. 
 
27 
HCC(CH2)4CO-Val(Me)-Agl(Me)-Val-Ala(Me)-Phe(Me)-OH (27) Employing the 
protocol described above for the synthesis of peptide 12 using Fmoc-Agl-Val-OH (462 mg, 
3 eq.) in the second coupling, followed by permethylation, peptide 27 (8.3 mg, 3%) was 
prepared and shown to be >95% pure by LC-MS analysis [50−90% MeOH (0.1% FA) in 
H2O (0.1% FA), 14 min, RT 9.12 min]. 
 
28 
HCC(CH2)4CO-Val(Me)-Val(Me)-Agl(Me)-Ala-Phe(Me)-OH (28) Employing the 
protocol described above for the synthesis of peptide 12 using Fmoc-Agl-Ala-OH (359 mg, 
3 eq.) in the second coupling, followed by permethylation, peptide 28 (6.7 mg, 2%) was 
prepared and shown to be >95% pure by LC-MS analysis [50−90% MeOH (0.1% FA) in 
H2O (0.1% FA), 14 min, RT 9.01 min]. 





HCC(CH2)4CO-Agl-Val-Val-Ala-Phe-NH(CH2)6NH2 (29) Employing the protocol 
described above for the synthesis of peptide 18 using Fmoc-Agl-Val-OH (462 mg, 3 eq.) in 
the fourth coupling, peptide 29 (7.5 mg, 3%) was prepared and shown to be >95% pure by 
LC-MS analysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 6.72 min]. 
 
30 
HCC(CH2)4CO-Val-Agl-Val-Ala-Phe-NH(CH2)6NH2 (30) Employing the protocol 
described above for the synthesis of peptide 18 using Fmoc-Agl-Val-OH (462 mg, 3 eq.) in 
the third coupling, peptide 30 (8.4 mg, 3%) was prepared and shown to be >95% pure LC-
MS analysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 6.83 min]. 
 
31 
HCC(CH2)4CO-Val-Val-Agl-Ala-Phe-NH(CH2)6NH2 (31) Employing the protocol 
described above for the synthesis of peptide 18 using Fmoc-Agl-Ala-OH (359 mg, 3 eq.) in 
the second coupling, peptide 31 (9.1 mg, 3%) was prepared and shown to be >99% pure 
by LC-MS analysis [30−95% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 7.42 min]. 
 
32 





HCC(CH2)4CO-Val-Val-Val-Agl-Phe-NH(CH2)6NH2 (32) and HCC(CH2)4CO-Val-
Val-Val-Agl-D-Phe-NH(CH2)6NH2 (R-32) Employing the protocol described above for 
the synthesis of peptide 18 using Fmoc-Agl-(D,L)-Phe-OH (1.03 g, 3 eq.), the mixture of 
two diastereoisomers was prepared and separated by HPLC on C18 column using a gra-
dient of 50% to 90% MeOH in H2O to obtain peptide 32 (1 mg, 1%), which was shown to 
be >95% pure by LC-MS analysis [50−90% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 
5.31 min] and peptide 39 (0.9 mg, 1%), which was shown to be >95% pure by LC-MS anal-




ploying the protocol described above for the synthesis of peptide 17 using Fmoc-Agl-Val-
OH (462 mg, 3 eq.) in the fourth coupling, followed by permethylation and coupling to 
1,6-diaminohexane, peptide 33 (9.5 mg, 3%) was prepared and shown to be >99% pure by 




ploying the protocol described above for the synthesis of peptide 17 using Fmoc-Agl-Val-
OH (462 mg, 3 eq.) in the third coupling, followed by permethylation and coupling to 1,6-
diaminohexane, peptide 34 (8.3 mg, 3%) was prepared and shown to be >95% pure by LC-
MS analysis [50−90% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 6.86 min]. 






ploying the protocol described above for the synthesis of peptide 17 using Fmoc-Agl-Ala-
OH (359 mg, 3 eq.) in the second coupling, followed by permethylation and coupling to 
1,6-diaminohexane, peptide 35 (6.7 mg, 2%) was prepared and shown to be >95% pure by 
LC-MS analysis [50−90% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 6.80 min]. 
 
HCC(CH2)4CO-(5-Me)Nai-Val-Val-Ala-Phe-OH (36) Employing the protocol de-
scribed above for the synthesis of peptide 15 using Fmoc-(5-Me)Nai-Val-OH (318 mg, 2 
eq.) in the third coupling, peptide 36 (8.8 mg, 9%) was prepared and shown to be >99% 
pure by LC-MS analysis [50−90% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 5.34 
min]. 
 
HCC(CH2)4CO-Val-(5-Me)Nai-Val-Ala-Phe-OH (37) Employing the protocol de-
scribed above for the synthesis of peptide 15 using Fmoc-(5-Me)Nai-Val-OH (318 mg, 2 
eq.) in the second coupling, peptide 37 (4.7 mg, 4%) was prepared and shown to be >99% 
pure by LC-MS analysis [50−90% MeOH (0.1% FA) in H2O (0.1% FA), 14 min, RT 4.41 
min]. 
5. Conclusions 
The unsaturated lipid tail and the C-terminal acid and carboxamide functions of al-
miramide peptides have previously been shown to have relevance for activity against 
trypanosomatid parasites [24,25]. Moreover, active almiramide analogs possessing sugar 
amino acids were suggested to adopt bent structures [31]. The influences on anti-parasite 
activity of amide N-methylation and turn-inducing Agl and Nai residues within almira-
mide peptides have now been investigated in wild type and resistant strains of L. infatum 
and compared with macrophage cytotoxicity. Peptide amides exhibited consistently bet-
ter activity than their C-terminal acid counterparts. Within a set of almiramide 1,6-dia-
minohexane amides, more potent peptides with relatively high selectivity were typically 
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obtained without methylation (e.g., 16) and with a single methyl group in MePhe5 almira-
mide 22 than with analogs possessing a methyl amide at other positions and with per-
methylated analog 17. On the other hand, permethylated and MeVal1 peptide amides 17 
and 18 exhibited μM inhibitory activity against the amphotericin B resistant strain with 
high therapeutic indices. Replacement of amino acid residues by turn-inducing counter-
parts caused typically losses of activity against the L. infatum strains; however, permeth-
ylated Agl2 amide had similar activity and better selectivity against wild type L. infatum 
compared to permethylated analog 17. Although studies of the consequences of such 
structural modifications on metabolism and mechanism of action are in progress, con-
formers extended about the central residues and mobile at the extremities of the peptide 
may favor almiramide activity. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
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